RESULTS: Of 371 patients enrolled in active surveillance, 46(12.4%) pursued delayed intervention. Patients who pursued delayed intervention spent a median 12 months on surveillance (IQR5.5-23.6), had better functional status (p<0.01), and had greater median growth rate versus those who remained on surveillance (0.38 vs 0.05, p<0.001). Indications for intervention included growth rate >0.5cm/year for 23 (50%) patients, patient preference for 22 (47.8%) patients, and qualification for renal transplant in 1 (2.2%) patient. Thirty-two patients (69.6%) underwent nephron-sparing surgery, 5 (10.9%) underwent radical nephrectomy, and 9 (19.6%) underwent percutaneous cryoablation. Renal mass biopsy was utilized in 37 (11.4%) and 15 (32.7%) patients in the AS and delayed intervention arms, respectively, (p[0.04). No patients experienced metastatic progression or died of kidney cancer.
INTRODUCTION AND OBJECTIVES:
The treatment options for small renal masses (SRM, 4 cm) are associated with different costs despite all generally having excellent long-term prognoses. To better understand the cost implications of treating small renal masses, we calculated and determined the breakdown of lifetime costs for competing SRM treatments.
METHODS: A Markov model with a 3-month cycle length was developed to estimate lifetime costs of treating SRMs from a payer's perspective. Management options included (1) immediate strategies with open partial nephrectomy (OPN), robotic partial nephrectomy (RPN), or percutaneous ablation (PA), and (2) delayed strategies with active surveillance followed potentially by OPN, RPN, or PA. The base case scenario was a cohort of healthy 65-year-old patients with asymptomatic unilateral SRMs. Key inputs were derived from the Premier Healthcare Database, a nationally representative hospital discharge database in the United States. Costs were inflated to 2016 USDs. Deterministic and probabilistic sensitivity analyses were performed to test alternative clinical scenarios and the model robustness, respectively. RESULTS: For the base case, immediate OPN was the least costly strategy ($111,981) while PA was the most expensive ($118,767), due to the higher cost of metastatic disease for PA. Active surveillance increased the OPN and RPN costs, due to increased probability of radical nephrectomy and associated chronic kidney disease (CKD), but reduced costs for PA. Compared to OPN, RPN was more costly ($1400 to $1800) across various clinical scenarios except for high volume surgeons (>15/year) and unhealthy patients (Charlson score !2) at which point RPN was associated with fewer complications. The primary financial burden associated with immediate treatment of SRM was post-treatment surveillance imaging costs (Figure) .
CONCLUSIONS: The lifetime cost for all SRM treatment options is high ($110,000 to $120,000). This cost varies by probability of complications, incidence of metastasis, and risk of CKD. Regardless of treatment modality, the majority of the medical expenditure is the posttreatment imaging, which thus represents the ideal target to minimize the overall financial burden of kidney cancer.
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MP14-12 NEPHRECTOMY DELAY MORE THAN TEN WEEKS FROM DIAGNOSIS IS ASSOCIATED WITH DECREASED OVERALL SURVIVAL IN PT3 RCC
Jiping Zeng*, Ken Batai, Benjamin Lee, Tucson, AZ INTRODUCTION AND OBJECTIVES: To evaluate the impact of time interval between diagnosis to definitive surgery on the outcomes of patients with T3 renal cell carcinoma, and to investigate the potential causes of delay.
METHODS: Using the National Cancer Database we retrospectively reviewed the records of patients with pT3 renal cell carcinoma treated with radical nephrectomy or nephron sparing surgery between 2004 and 2015. Patients with metastatic disease were excluded. The cohort was categorized based on time interval from diagnosis to surgery. The primary outcome was five-year overall survival (OS), which was calculated using vital status (alive or death) and last date of contact since definitive surgery. Cox proportional hazards models were fitted to assess relations between these intervals and 5-year OS, adjusting first for patient demographics and then for disease severity. Multivariate linear regression was used to search for potential risk factors associated with delayed surgery.
RESULTS: A total of 22,653 patients were included in the analysis. The median follow-up time was 31 months and the overall mortality rate at 5-year follow-up was 42.9%. The median interval from diagnosis to definite surgery was 30 days and 85.3% of patients underwent
